Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.